Freeline Therapeutics Holdings plc

NasdaqCM:FRLN Stock Report

Market Cap: US$28.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Freeline Therapeutics Holdings Balance Sheet Health

Financial Health criteria checks 4/6

Freeline Therapeutics Holdings has a total shareholder equity of $30.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $49.2M and $19.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$29.45m
EquityUS$30.04m
Total liabilitiesUS$19.18m
Total assetsUS$49.22m

Recent financial health updates

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Apr 11
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Dec 20
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Recent updates

Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

Jul 13
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Apr 11
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Dec 20
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Aug 30
We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Freeline gains as NEJM publishes long-term data for hemophilia therapy

Jul 21

Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

May 05
Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Jan 13
Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Sep 30
Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

Jun 03
Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Feb 18
What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Financial Position Analysis

Short Term Liabilities: FRLN's short term assets ($34.0M) exceed its short term liabilities ($17.5M).

Long Term Liabilities: FRLN's short term assets ($34.0M) exceed its long term liabilities ($1.7M).


Debt to Equity History and Analysis

Debt Level: FRLN is debt free.

Reducing Debt: FRLN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FRLN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FRLN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies